HCR Monthly Blog

Key 2015 Obamacare Actions that U.S. Rx Manufacturers Should Be Considering

December 11th, 2014 Tom Norton

At first glance Obamacare developments for the American Rx industry in 2015 appear fairly benign. However, digging deeper suggests that each, in its own way, could cause various actions with potential for substantial uncertainty for the U.S. pharmaceutical industry next year. If your response to this profound observation was, “Really, what’s new?” — read on. read more

 

America’s “Great Generic Wars” and the Canadian-European Trade Agreement

August 26th, 2014 Tom Norton

As a young pharmaceutical manager, I became involved in America’s “Great Generic Wars” in the late 1970’s. It was an epic struggle between the U.S. brand name manufacturers and numerous generic drug producers that wanted to make generics widely available on the U.S. market. Depending on your point of view, the wars were fought over read more

 

The US Rx Tax Exodus: Is Something “Probably Wrong” with Our System?

July 9th, 2014 Tom Norton

As I read the latest reports of yet another big US Rx firm, this time AbbVie, trying to pull off a “tax inversion” takeover of the Irish-based Shire, I couldn’t help but wonder, what the heck is going on here? Right now, it feels like most major US corporations, especially pharmas, are literally running away read more

 

What Does ‘Off Label’ Mean in 2014?

June 12th, 2014 Tom Norton

Years ago, while sitting in an Rx company lunch room, I was listening to one of the company’s top sales reps discuss the commercial progress a recently launched prescription was making. The rep said that the product was selling “OK” under its FDA approved, indicated therapeutic area. However, he quietly said, “It’s not the approved read more